Malignant Pleural Mesothelioma: Present Status and Future Directions

Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Results after Intraoperative Therapy in Malignant Pleural Mesothelioma

Pp. 469-478 (10)

Shamus R. Carr and Joseph S. Friedberg

Abstract

Malignant pleural mesothelioma (MPM) is a virulent disease that is essentially incurable. Although surgery cannot currently be considered standard of care, there is general agreement that a certain subset of patients appear to benefit from surgery-based multimodal treatments beyond what would be expected with the current standard of care, pemetrexed-based chemotherapy alone. Exactly who those patients are remains to be defined. One intuitively appealing aspect of surgery-based therapies is that they allow for the employment of an intraoperative adjuvant therapy. There are multiple intraoperative adjuvant therapies, each with their own advantages and disadvantages. This chapter is a review of these treatments.

Keywords:

Intraoperative therapy, intrapleural chemotherapy, outcomes, photodynamic therapy.

Affiliation:

University of Maryland School of Medicine, Division of Thoracic Surgery, 29 Greene St, Suite 504, 21201 Baltimore, MD, United States.